Precision medicine for prostate cancer-improved outcome prediction for low-intermediate risk disease using a six-gene copy number alteration classifier.

Autor: Lautert-Dutra W; Department of Genetics, Medicine School of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil., Dos Reis RB; Division of Urology, Department of Surgery and Anatomy, Medicine School of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil., Squire JA; Department of Genetics, Medicine School of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil. jsquireinsp@gmail.com.; Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada. jsquireinsp@gmail.com.
Jazyk: angličtina
Zdroj: British journal of cancer [Br J Cancer] 2023 Jun; Vol. 128 (12), pp. 2163-2164. Date of Electronic Publication: 2023 Apr 29.
DOI: 10.1038/s41416-023-02289-9
Abstrakt: A multiplex 6-gene copy number classifier was used to distinguish between low- or intermediate-risk prostate cancer patients. The study analysed a cohort of 448 patients and previously published datasets from radical prostatectomies. The classifier performs better than conventional stratification methods, is low cost, and can be performed easily in clinical laboratories.
(© 2023. The Author(s), under exclusive licence to Springer Nature Limited.)
Databáze: MEDLINE
Externí odkaz: